What do we know about atypical femoral fractures? Insights and enigmas

TitreWhat do we know about atypical femoral fractures? Insights and enigmas
Type de publicationArticle de revue
AuteurAudran, Maurice , Cortet, Bernard, Thomas, Thierry
TypeArticle scientifique dans une revue à comité de lecture
Année2011
LangueAnglais
Date2011 Dec
Numéro6
Pagination568-571
Volume78
Titre de la revueJoint Bone Spine
ISSN1778-7254
Mots-clésBone Density Conservation Agents, Diphosphonates, Dose-Response Relationship, Drug, Femoral Fractures, Hip Fractures, Humans, osteoporosis, Prevalence, Risk Factors
Résumé en anglais

Although the existence of atypical femoral fractures is well established and bisphosphonate therapy is thought to be a major risk factor, the underlying mechanisms are poorly understood. Epidemiological data show that atypical femoral fractures account for only a small proportion of diaphyseal subtrochanteric femoral fractures, being about 100 times less common than proximal femoral fractures. Consequently, the existence of atypical femoral fractures does not call into question the extremely favorable risk/benefit ratio of bisphosphonate therapy in patients with osteoporosis. Clearly, the number of fractures prevented by bisphosphonate therapy far exceeds the number of atypical femoral fractures potentially related to bisphosphonates.

Notes

On behalf of the Bone division of the French Society for Rheumatology

URL de la noticehttp://okina.univ-angers.fr/publications/ua10395
DOI10.1016/j.jbspin.2011.03.015
Identifiant (ID) PubMed21592839